FAQ: What is the Safety Profile of Ixekizumab in PsA and axSpa

Wendy Simmons, PA-C, a rheumatology specialist at Carolina Arthritis Associates in Wilmington, North Carolina, explores the safety profile of Ixekizumab, a biologic therapy for psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). With over 26 years of clinical experience, Wendy provides essential insights into potential risks, patient monitoring, and long-term safety considerations for those receiving this treatment.While Ixekizumab is generally well-tolerated, common side effects include injection site reactions, upper respiratory infections, nausea, and fungal infections. More serious risks, such as tuberculosis (TB), bacterial and viral infections, and neutropenia (low neutrophil counts), require careful monitoring. Additionally, some patients may experience worsening of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, making gastrointestinal evaluation crucial.To ensure safe and effective treatment, providers should screen for TB before initiating therapy, avoid live vaccines, and monitor blood counts regularly. Caution is advised when combining Ixekizumab with other immunosuppressive agents due to the potential for additive immune suppression.For more in-depth information on Ixekizumab and its safety in rheumatologic conditions, visit the RhAPP website or explore additional educational content on the RhAPP ACE App.